Background The efficacy of antiplatelet therapy (APT) after aneurysmal subarachnoid
hemorrhage (aSAH) remains unclear. We performed a systematic review and meta-analysis …

Antiplatelet treatment (APT) has been reported to be used in some patients with aneurysmal
subarachnoid hemorrhage (aSAH) after endovascular treatment, but there is controversy …

OBJECTIVE Delayed cerebral ischemia (DCI) is a potentially preventable cause of morbidity
and mortality after aneurysmal subarachnoid hemorrhage (aSAH). The authors performed a …

Antiplatelet therapy (AT) may serve to reduce the effects of aneurysmal subarachnoid
hemorrhage (aSAH)-induced pro-coagulant state in the cerebral circulation. Several studies …

Background and Purpose—Observational studies suggest that platelet inhibitors reduce the
risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage and …

Background The pathophysiology of delayed cerebral ischemia (DCI) after aneurysmal
subarachnoid hemorrhage (aSAH) may include platelet activation and microthrombi …

Objective There is limited evidence on the use of antiplatelet therapy (APT) to reduce the risk
and morbidity of cerebral aneurysmal rupture. This analysis retrospectively assessed APT …

Background The case fatality in aneurysmal subarachnoid hemorrhage (aSAH) is 50%
because of the initial hemorrhage or subsequent complications, such as aneurysmal …

BACKGROUND AND PURPOSE: Observational studies suggest that platelet inhibitors
reduce the risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid …

Platelet activation has been postulated to be involved in the pathogenesis of delayed
cerebral ischemia (DCI) and cerebral vasospasm (CVS) after aneurysmal subarachnoid …